Protalix BioTherapeutics is no longer asking the market to fund a science story with an empty warehouse. The Carmiel plant now ships two approved enzyme replacement therapies through Chiesi, Pfizer, and Brazil's Fiocruz, and the March European decision that lets stable Fabry patients take Elfabrio every four weeks rather than every two weeks turned a label claim into cash. That approval triggered a twenty-five million Chiesi milestone booked in the first quarter, which is why first-half net income flipped to a large profit after a prior-year loss. The investment debate is narrower than the headline profit suggests. Either partnered goods shipments, led by Elfabrio, keep compounding after that one-time payment and let the company pay for its gout study out of operations, or the print was a milestone event dressed up as a franchise inflection.
The tension sits in the mix, not the brand names. First-half total revenue more than doubled, yet roughly half of that print is the Chiesi check rather than vials leaving the plant. Goods revenue still rose, and the June quarter did the heavy lifting after a thin first quarter, with higher shipments to Chiesi and Fiocruz offsetting a pullback in Pfizer purchases that had been inflated by last year's manufacturing disruption at the partner. Mid-year cash and short-term deposits sat near forty-one million, with no funded debt and no warrants left on the capital structure. That is a cleaner residual claim than most micro-cap biotechs carry. It is also a working-capital business: inventory and receivables both expanded as the plant loaded partners, so the cash pile is not a pure earnings residual.
The next several quarters resolve a simple question. Can Elfabrio goods land inside the mid-thirties full-year band management restated in August, and does that run-rate hold once the milestone year rolls off, while the RELEASE gout study keeps enrolling toward a second-half twenty twenty-seven readout? If partner orders stay lumpy and the United States still withholds monthly dosing, the equity is a small contract manufacturer with a long-dated clinical option. If European conversion to monthly dosing lifts Chiesi pull-through and the plant stays profitable after the one-time fades, the market is paying a manufacturer multiple for a franchise that has already shown it can throw off cash.